Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
← catalyst calendarNCT07309432 · readout in 193 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
350estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-10 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergic Conjunctivitis
Interventions
- Drug: REGN5713 — also filed as Bremzalerbart
- Drug: REGN5715 — also filed as Atisnolerbart
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFOcular itch score in participants receiving REGN5713-5715 compared to placebo
measured At Day 8 post-Conjunctival Allergen Challenge (CAC)
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed